Vasil'ev A V, Kazennova E V, Bobkova M R
Vopr Virusol. 2011 May-Jun;56(3):32-7.
The authors studied the prevalence of mutations associated with resistance to the CCRS coreceptor antagonists maraviroc and vicriviroc in Russia. Most (93.6%) patients infected with HIV-1 genetic subtype A (IDU-A), predominant in the CIS countries, were found to have maraviroc resistance mutations. These mutations appear to reflect the natural genome polymorphism characteristic of the variant IDU-A. Maraviroc resistance mutations were of limited occurrence (2.8%) among the samples of virus subtype B in Russia. There were no vicriviroc resistance mutations in both the HIV-1 genetic variant IDU-A and the samples of virus subtype B. There is a need for further clinical studies evaluating the real impact of these mutations on the efficacy of maraviroc in patients infected with the HIV-1 genetic variant IDU-A.
作者们研究了俄罗斯与对CCR5共受体拮抗剂马拉维若和维立维若耐药相关的突变的流行情况。在独联体国家占主导的感染HIV-1基因A亚型（注射吸毒者-A型）的大多数（93.6%）患者中，发现存在马拉维若耐药突变。这些突变似乎反映了变异的注射吸毒者-A型所特有的自然基因组多态性。在俄罗斯的病毒B亚型样本中，马拉维若耐药突变的发生率有限（2.8%）。在HIV-1基因变异注射吸毒者-A型和病毒B亚型样本中均未发现维立维若耐药突变。有必要开展进一步的临床研究，以评估这些突变对感染HIV-1基因变异注射吸毒者-A型患者中马拉维若疗效的实际影响。
